Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital.'Since our company's inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage,' said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio.

开创下一代双特异性抗体和抗体-药物偶联物（ADC）疗法的临床阶段生物技术公司Allink Biotherapeutics今天宣布成功完成4200万美元的a系列融资。融资回合由兰芝风险投资公司（Lanchi Ventures）牵头，兰芝风险投资公司是一家杰出的全球早期技术投资者，以支持突破性创新而闻名，新投资者的精英财团（包括Yuanbio Venture Capital、Legend Capital和C＆D Emerging Industry Equity Investment）也参与了这一轮融资，现有股东高融风险投资公司（Gaorong Ventures）和Med Fine CapitalAllinkBio创始人兼首席执行官惠丰博士说，自公司成立一年多以来，AllinkBio已迅速从领先资产PCC发展到临床开发阶段。

'We are grateful for the continued support from existing shareholders and delighted to welcome new investors who recognize both our scientific excellence and capability of translating scientific findings into clinical applications. Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases.

“我们感谢现有股东的持续支持，并欢迎新投资者认可我们的科学卓越性和将科学发现转化为临床应用的能力。他们的支持使我们能够加速开发跨越多种模式的多样化管道，包括针对肿瘤学和免疫学疾病的下一代ADC和双特异性抗体。

Looking ahead, we are poised to achieve multiple pipeline milestones in the coming months as we pursue our long-term mission of bringing innovative therapeutics to patients with significant unmet medical needs.''AllinkBio's exceptional execution speed and quality in advancing its lead program from preclinical to clinical stage, led by Dr.

展望未来，我们将在未来几个月实现多个管道里程碑，因为我们将致力于为严重未满足医疗需求的患者带来创新疗法的长期使命。”AllinkBio以其卓越的执行速度和质量将其领先项目从临床前阶段推进到临床阶段，由Dr。

Feng, one of the leading figures in China's biopharmaceutical industry, demonstrates the company's high competitiveness in the field,' said Lanchi Ventures. 'AllinkBio's innovative.

兰芝风险投资公司（LanchiVentures）说，冯是中国生物制药行业的领军人物之一，展示了该公司在该领域的高度竞争力AllinkBio的创新。